|
SCO1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.91586763015539E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.85964610166911E-12 |
| Normal-vs-Stage2 |
1.537610E-01 |
| Normal-vs-Stage3 |
8.75965966429249E-14 |
| Normal-vs-Stage4 |
1.62703184258817E-12 |
| Stage1-vs-Stage2 |
2.418300E-03 |
| Stage1-vs-Stage3 |
9.029700E-02 |
| Stage1-vs-Stage4 |
6.648900E-04 |
| Stage2-vs-Stage3 |
2.364900E-04 |
| Stage2-vs-Stage4 |
4.18930000001261E-06 |
| Stage3-vs-Stage4 |
1.167170E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.15740750317173E-12 |
| Normal-vs-AfricanAmerican |
1.51029999950758E-07 |
| Normal-vs-Asian |
6.46489528577376E-11 |
| Caucasian-vs-AfricanAmerican |
7.013200E-01 |
| Caucasian-vs-Asian |
3.385200E-01 |
| AfricanAmerican-vs-Asian |
7.430800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.19379950369591E-10 |
| Normal-vs-Female |
1.26599841721031E-11 |
| Male-vs-Female |
3.534200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.99595895367111E-12 |
| Normal-vs-Age(41-60Yrs) |
1.34809940988134E-11 |
| Normal-vs-Age(61-80Yrs) |
1.65949999997306E-06 |
| Normal-vs-Age(81-100Yrs) |
3.079300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.239000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.176400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.740800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.200300E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.179600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.831000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.018300E-03 |
| Classical-VS-Follicular |
4.24709999999884E-05 |
| Classical-VS-Other |
3.321600E-01 |
| Classical-VS-Normal |
1.62492241884138E-12 |
| Tall-VS-Follicular |
7.09120000497165E-08 |
| Tall-VS-Other |
9.908400E-01 |
| Tall-VS-Normal |
4.10782519111308E-15 |
| Follicular-VS-Other |
5.828400E-02 |
| Follicular-VS-Normal |
1.307940E-02 |
| Other-VS-Normal |
1.172250E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.87059999712247E-08 |
| Normal-vs-N1 |
1.04471986617227E-13 |
| N0-vs-N1 |
9.60039999999829E-05 |
|
|
